Avant Technologies Drives Gene Therapy Market to $36.55 Billion by 2032

Written by Emily J. Thompson, Senior Investment Analyst

MDGL-0.37%

CRSP-0.63%

VRTX-0.47%

Source: PRnewswire

Updated: Jan 02 2026

0mins

Source: PRnewswire

Market Growth Potential: The gene therapy market is projected to reach $36.55 billion by 2032, growing at a compound annual rate of 17.98%, reflecting a surge in demand for curative treatments that drives investor confidence in functional cures.
FDA Approval of New Therapies: The FDA's approval of three transformative cell therapies in December marks a shift from experimental concepts to commercial reality, providing new market opportunities for companies like Avant Technologies.
Strategic Partnerships: Avant's collaboration with SGAustria focuses on developing cell-based therapies for type 1 and insulin-dependent type 2 diabetes using encapsulation technology to address immune rejection, which is expected to significantly enhance patient quality of life.
Anti-Aging Therapy Development: Avant's second joint venture, Klothonova, partners with Austrianova to develop anti-aging therapies that restore circulating α-Klotho levels using genetically modified human cells, with potential markets spanning Alzheimer's disease and cardiovascular conditions.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like MDGL with instant alerts to capture every critical market movement.

Sign up for free to build your custom watchlist and receive professional-grade stock notifications.

MDGL

$494.69+Infinity%1D

Analyst Views on MDGL

Wall Street analysts forecast MDGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDGL is 636.22 USD with a low forecast of 527.00 USD and a high forecast of 900.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Analyst Rating

10 Buy

2 Hold

0 Sell

Strong Buy

Current: 496.540

Low

527.00

Averages

636.22

High

900.00

Current: 496.540

Low

527.00

Averages

636.22

High

900.00

Barclays

initiated

$964

2026-01-27

New

Reason

Barclays

Price Target

$964

AI Analysis

2026-01-27

New

initiated

Reason

Barclays initiated coverage of Madrigal Pharmaceuticals with an Overweight rating and $964 price target. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds."

Citizens

Outperform

maintain

$527 -> $745

2026-01-20

Reason

Citizens

Price Target

$527 -> $745

2026-01-20

maintain

Outperform

Reason

Citizens raised the firm's price target on Madrigal Pharmaceuticals to $745 from $527 and keeps an Outperform rating on the shares. Rezdiffra's extended intellectual property coverage and multiple shots on goal with combination candidates lends more confidence in MASH revenues extending into the 2040s, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MDGL

Unlock Now

About MDGL

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.